Scandinavia still reluctant to resume vaccination with AstraZeneca
The AstraZeneca vaccine has been found to be safe and effective by the European Medicines Agency.
AP - Matthias Schrader
Text by: RFI Follow
2 min
Since the European Medicines Agency gave the green light to the AstraZeneca vaccine again, vaccination has resumed in most European countries, but not in Scandinavia.
Norway, Sweden and Denmark have chosen to make the resumption of injections conditional on more in-depth evaluations of rare but serious coagulation disorders which have appeared in vaccinated persons.
Publicity
Read more
With our correspondent in Stockholm,
Frédéric Faux
The AstraZeneca vaccine has been cleared by European authorities, but it still remains suspect in the eyes of the Scandinavians, who continue to suspend its use.
In Norway, an investigation is underway after five patients were admitted to Oslo hospital with thrombosis problems, between 3 and 12 days after being vaccinated.
Two died.
Researchers at the same hospital have also established a link between the vaccine and the
formation of blood clots
in three patients.
In Denmark, two people fell seriously ill after being vaccinated, one of whom died.
Two suspicious deaths also in Sweden.
Very isolated cases, which do not call into question
the benefit / risk ratio of the vaccine
, but which the various authorities want to examine more closely.
Because pharmaco-vigilance, in Scandinavia, is very developed.
It is also in these same countries that a link was established in 2010 between the HIN1 influenza vaccine and a wave of narcolepsy, a sleeping sickness that particularly affected young people.
Newsletter
Receive all international news directly in your mailbox
I subscribe
Follow all the international news by downloading the RFI application
google-play-badge_FR
Sweden
Denmark
Norway
Vaccines
Health and medicine